Modality
mAb
MOA
KRASG12Ci
Target
PLK4
Pathway
JAK/STAT
HCCFTDCTCL
Development Pipeline
Preclinical
~Aug 2013
→ ~Nov 2014
Phase 1
~Feb 2015
→ ~May 2016
Phase 2
~Aug 2016
→ ~Nov 2017
Phase 3
~Feb 2018
→ ~May 2019
NDA/BLA
Aug 2019
→ Aug 2028
NDA/BLACurrent
NCT08448577
2,733 pts·FTD
2019-08→2028-08·Terminated
2,733 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-252.4y awayPh3 Readout· FTD
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-08-25 · 2.4y away
FTD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08448577 | NDA/BLA | FTD | Terminated | 2733 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niralucimab | Ionis | Phase 1 | ALK |